ABBV: Analysis & Opinions

  1. Repros Delays ZA-301 Study Results - Analyst Blog

    January 31, 2013
    Repros Therapeutics Inc. (RPRX) recently announced that results from the first pivotal study (ZA-301) of Androxal ...
  2. Biogen Advances with MS Candidate - Analyst Blog

    January 25, 2013
    Biogen Idec (BIIB) recently announced positive top-line data on its phase III multiple sclerosis candidate, ...
  3. Abbott Beats on EPS, Guides In-Line - Analyst Blog

    January 23, 2013
    Abbott Labs (ABT) reported fourth quarter 2012 earnings of $1.51 per share, a penny ahead of the Zacks Consensus ...
  4. Abbott's ABSORB in Phase III Trial - Analyst Blog

    January 09, 2013
    Abbott Laboratories (ABT) recently announced that its Absorb Bioresorbable Vascular Scaffold (BVS) device has moved ...
  5. Abbott Labs Spins Off AbbVie: Which Is The Better Buy?

    January 04, 2013
    January 2 was the first day of trading for the pharmaceutical spin-off.
  6. Abbott Spins Off Pharma Business - Analyst Blog

    January 03, 2013
    Abbott Laboratories (ABT) recently announced that the company has separated its research-based pharmaceuticals ...
Marketplace
Trading Center